Topilutamide

Topilutamide
Clinical data
Trade names Eucapil
Synonyms Fluridil; BP-766
Routes of
administration
Topical[1][2][3][4][5]
Drug class Nonsteroidal antiandrogen
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C13H11F6N3O5
Molar mass 403.234 g/mol
3D model (JSmol)

Topilutamide, known more commonly as fluridil and sold under the brand name Eucapil, is an antiandrogen medication which is used in the treatment of pattern hair loss in men and women.[6][1][2][3][4][5] It is used as a topical medication and is applied to the scalp.[1][2][3][4][5]

Topilutamide is a nonsteroidal antiandrogen (NSAA), or an antagonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT).[1][2][3][4][5]

Topilutamide was introduced for medical use in 2003.[7] It is marketed only in the Czech Republic and Slovakia.[8]

Medical uses

Topilutamide is used as a topical medication in the treatment of pattern hair loss in men and women.[1][2][3][4][5][3]

Available forms

As Eucapil, topilutamide is available as a 2% topical formulation intended for application to the scalp.[4]

Pharmacology

Pharmacodynamics

Topilutamide is a antagonist of the AR, the biological target of androgens like testosterone and DHT.[1][2][3][4][5]

Pharmacokinetics

Topilutamide is a topical medication and is applied to the scalp.[1][2][3][4][5]

Chemistry

Topilutamide is a nonsteroidal compound and is closely related to other NSAAs such as flutamide and bicalutamide.[7]

History

Topilutamide was introduced for medical use in 2003.[7]

Society and culture

Generic names

Topilutamide is the generic name of the drug and its INN.[9][10][11] It is also known more commonly as fluridil.[6] Topilutamide is also known by its former developmental code name BP-766.[6]

Brand names

Topilutamide is marketed by Interpharma Praha under the brand name Eucapil.[7][3]

Availability

Topilutamide is available only in Europe in the Czech Republic and Slovakia.[8]

See also

References

  1. 1 2 3 4 5 6 7 Sovak M, Seligson AL, Kucerova R, Bienova M, Hajduch M, Bucek M (2002). "Fluridil, a rationally designed topical agent for androgenetic alopecia: first clinical experience". Dermatol Surg. 28 (8): 678–85. doi:10.1046/j.1524-4725.2002.02017.x. PMID 12174057.
  2. 1 2 3 4 5 6 7 Robert S. Haber; Dowling Bluford Stough (2006). Hair Transplantation. Elsevier Health Sciences. pp. 7–. ISBN 1-4160-3104-9.
  3. 1 2 3 4 5 6 7 8 9 Scripta Medica. 2006. pp. 45,53–54. Fluridil was developed as a topical antiandrogen, suitable for the treatment of hyperandrogenic skin syndromes. The cosmetic product Eucapil® containing 2% fluridil in isopropanol was tested in women with AGA in a 9-month open study. [...] In a clinical study conducted at our facility, fluridil in solution (Eucapil®, Interpharma Praha, Czech Republic) has been shown to be effective and safe in the treatment of men with androgenetic alopecia (30, 31).
  4. 1 2 3 4 5 6 7 8 Marc R. Avram; Nicole E. Rogers (30 November 2009). Hair Transplantation. Cambridge University Press. pp. 11–. ISBN 978-1-139-48339-1.
  5. 1 2 3 4 5 6 7 Kirby RS, Carson CC, Kirby MG, White A (29 January 2009). Men's Health, Third Edition. CRC Press. pp. 362–. ISBN 978-1-4398-0807-8.
  6. 1 2 3 Seligson, Allen L; Campion, Brian K; Brown, Jason W; Terry, Ron C; Kucerova, Renata; Bienova, Martina; Hajduch, Marian; Sovak, Milos (2003). "Development of fluridil, a topical suppressor of the androgen receptor in androgenetic alopecia" (PDF). Drug Development Research. 59 (3): 292–306. doi:10.1002/ddr.10166. ISSN 0272-4391.
  7. 1 2 3 4 Hermkens PH, Kamp S, Lusher S, Veeneman GH (2006). "Non-steroidal steroid receptor modulators". IDrugs. 9 (7): 488–94. doi:10.2174/0929867053764671. PMID 16821162.
  8. 1 2 Eucapil website
  9. https://chem.nlm.nih.gov/chemidplus/rn/260980-89-0
  10. http://www.who.int/medicines/publications/druginformation/innlists/PL91.pdf
  11. United States International Trade Commission (2008). Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic-Central America-United States Free Trade Agreement With Respect to Costa Rica. DIANE Publishing. pp. 18–. ISBN 978-1-4578-1723-6.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.